GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Vericel Corp (NAS:VCEL) » Definitions » FCF Margin %

Vericel (Vericel) FCF Margin % : -13.29% (As of Mar. 2024)


View and export this data going back to 1997. Start your Free Trial

What is Vericel FCF Margin %?

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Vericel's Free Cash Flow for the three months ended in Mar. 2024 was $-6.8 Mil. Vericel's Revenue for the three months ended in Mar. 2024 was $51.3 Mil. Therefore, Vericel's FCF Margin % for the quarter that ended in Mar. 2024 was -13.29%.

As of today, Vericel's current FCF Yield % is 0.09%.

The historical rank and industry rank for Vericel's FCF Margin % or its related term are showing as below:

VCEL' s FCF Margin % Range Over the Past 10 Years
Min: -91.12   Med: -5.86   Max: 13.53
Current: 0.98


During the past 13 years, the highest FCF Margin % of Vericel was 13.53%. The lowest was -91.12%. And the median was -5.86%.

VCEL's FCF Margin % is ranked better than
80.4% of 1041 companies
in the Biotechnology industry
Industry Median: -145.04 vs VCEL: 0.98


Vericel FCF Margin % Historical Data

The historical data trend for Vericel's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Vericel FCF Margin % Chart

Vericel Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
FCF Margin %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -8.31 12.04 13.53 6.14 3.95

Vericel Quarterly Data
Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.57 13.07 1.32 3.46 -13.29

Competitive Comparison of Vericel's FCF Margin %

For the Biotechnology subindustry, Vericel's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Vericel's FCF Margin % Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Vericel's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Vericel's FCF Margin % falls into.



Vericel FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Vericel's FCF Margin for the fiscal year that ended in Dec. 2023 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2023 )/Revenue (A: Dec. 2023 )
=7.798/197.516
=3.95 %

Vericel's FCF Margin for the quarter that ended in Mar. 2024 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2024 )/Revenue (Q: Mar. 2024 )
=-6.815/51.281
=-13.29 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Vericel FCF Margin % Related Terms

Thank you for viewing the detailed overview of Vericel's FCF Margin % provided by GuruFocus.com. Please click on the following links to see related term pages.


Vericel (Vericel) Business Description

Traded in Other Exchanges
Address
64 Sidney Street, Cambridge, MA, USA, 02139
Vericel Corp is a fully integrated, commercial-stage biopharmaceutical company, specialized in advanced therapies for sports medicine and severe burn care markets. It markets two cell therapy products in the United States, MACI (autologous cultured chondrocytes on porcine collagen membrane) and Epicel (cultured epidermal autografts). The company operates in one reportable segment: the research, product development, manufacture, and distribution of patient-specific, expanded cellular therapies for use in the treatment of specific diseases.
Executives
Dominick Colangelo director, officer: President and CEO 1000 WINTER ST., SUITE 2200, WALTHAM MA 02451
Zerbe Robert L Md director
Paul K Wotton director C/O ANTARES PHARMA, INC., 707 EAGLEVIEW BOULEVARD, SUITE 414, EXTON PA 19341
Sean C. Flynn officer: SVP, General Counsel C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Michael Halpin officer: Chief Operating Officer C/O VERICEL CORPORATION, 64 SIDNEY ST., CAMBRIDGE MA 02139
Jonathan Mark Hopper officer: Chief Medical Officer 64 SIDNEY STREET, CAMBRIDGE MA 02139
Jonathan Siegal officer: Principal Accounting Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Lisa Wright director C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Mara Joseph Anthony Jr officer: Chief Financial Officer C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Steven C Gilman director 110 HARTWELL AVENUE, LEXINGTON MA 02421
Sandra Pennell officer: VP and Corporate Controller C/O VERICEL CORPORATION, 64 SIDNEY STREET, CAMBRIDGE MA 02139
Gerard J Michel officer: CFO & VP , Corp. Development 420 CHIPETA WAY, SALT LAKE CITY UT 84108
Daniel Orlando officer: Chief Operating Officer P.O. BOX 376, ANN ARBOR MI 48105
Alan L Rubino director PO BOX 376, LOBBY L., ANN ARBOR MI 48105
Consonance Capital Management Lp 10 percent owner 1370 AVENUE OF THE AMERICAS, SUITE 3301, NEW YORK NY 10019

Vericel (Vericel) Headlines

From GuruFocus

Vericel to Report First-Quarter 2022 Financial Results on May 4, 2022

By GuruFocusNews GuruFocusNews 04-20-2022